Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1297-1309.doi: 10.12092/j.issn.1009-2501.2026.10.001
Yi LIU1(
), Wenhua YU2(
), Yunjian SONG3, Mingfeng JIN1, Xin JIANG1, Zhongqun WANG1,*(
)
Received:2025-10-22
Revised:2026-01-28
Online:2026-10-26
Published:2026-11-11
Contact:
Zhongqun WANG
E-mail:84413029@qq.com;ywh295667@163.com;wangtsmc@126.com
CLC Number:
Yi LIU, Wenhua YU, Yunjian SONG, Mingfeng JIN, Xin JIANG, Zhongqun WANG. Research on the role of STING1 in diabetic atherosclerotic blood vessels and retina[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1297-1309.
Fig.2 Effects of diabetic atherosclerosis on body weight, glucose and lipid metabolism and inflammatory levels ($\bar x$±s, n = 5) A: schematic diagram of the time point construction of the diabetic atherosclerosis model in ApoE−/− mice (Created by Figdraw). B: body weight changes in mice in the Control group (ApoE−/− + HFD) and DM group (ApoE−/− + HFD + STZ). C: changes in blood glucose of each group. D-G: levels of four blood lipids (TG, T-CHO, LDL-C, HDL-C) of each group. H-J: levels of inflammatory factors (IL-6, IL-1β, TNF-α) of each group. **P<0.01, ***P<0.001.
Fig.3 Diabetic atherosclerosis promotes the progression of vascular plaque and retinopathy ($\bar x $±s, n=5) A: gross view of the aorta of mice in the Control group and DM group. B: HE and Masson staining of aortic roots of two groups. Scale bar=200 μm. C: quantitative analysis of aortic plaque area/lumen area. D: quantitative analysis of collagen fiber content in aortic plaque. E: HE staining of retinal sections of two groups. Scale bar=20 μm.F: quantitative analysis of retinal thickness. G: PAS staining of retinal vascular sections of two groups. Scale bar=20 μm. H: comparison of cell-free capillary numbers. I: comparison of the endothelial cell to pericyte ratio (E/P) . *P<0.05, **P<0.01, ***P<0.001.
Fig.4 The expression of STING1 increases in diabetic atherosclerotic plaque and retinopathy ($\bar x $±s, n=5) A: Western blot was used to detect the expression of STING1 in the aorta of mice in the control group and DM group. B: quantitative analysis of STING1 protein expression. C: immunohistochemical staining of STING1 in aortic root sections of each group. The first row: Scale bar=200 μm; the second row: Scale bar=100 μm. D: semi-quantitative analysis of STING1 immunohistochemical staining of aortic root sections. E: immunohistochemical staining of STING1 retinal sections of each group. Scale bar=20 μm. F: semi-quantitative analysis of STING1 immunohistochemical staining of retinal sections. **P<0.01, ***P<0.001.
Fig.5 Generation of STING1?/?/ApoE?/? mice and their effects on inflammation ($\bar x $±s, n=5) A: design of the tmem173-201 transcript. B: genotype verification of STING1−/−/ApoE−/− mice (P: positive control, B6: negative control N: no-template control). C-E: changes in inflammatory factors (IL-6, IL-1β, TNF-α) in mice in the DM group (ApoE −/− + HFD + STZ) and STING1−/−/ApoE−/− group (STING1−/− /ApoE −/− + HFD + STZ). ***P<0.001.
Fig.6 STING1 knockdown reduces plaque formation and retinal damage ($\bar {\boldsymbol{x}} $±s, n=5) A: gross morphology of aortas in the DM group and STING1−/−/ApoE−/− group. B: HE and Masson staining of aortic roots in the two groups. Scale bar=200 μm. C: quantitative analysis of aortic plaque area/lumen area. D: quantitative analysis of collagen fiber content in aortic plaque. E: HE staining of retinal sections in the two groups. Scale bar=20 μm. F: imageJ quantitative analysis of retinal thickness. G: PAS staining of retinal vasculature in mice in two groups. Scale bar=20 μm. H: comparison of cell-free capillary numbers. I: comparison of endothelial cell to pericyte ratio (E/P). *P<0.05, **P<0.01, ***P<0.001.
Fig.7 STING1 deficiency inhibits pathological angiogenesis of plaques ($\bar x $±s, n=5) A: immunohistochemical staining of CD31, CD34, and LYVE-1 in the aortic roots of mice in the DM group and STING1−/−/ApoE−/− group. The first and third columns: Scale bar=200 μm; the second and fourth columns: Scale bar=100 μm. B-D: semi-quantitative analysis of aortic root sections by immunohistochemical staining of CD31, CD34, and LYVE-1. **P<0.01, ***P<0.001.
Fig.8 STING1 deficiency suppresses retinal pathological angiogenesis and correlates with disease severity ($\bar x $±s, n=5) A: immunohistochemical staining and semi-quantitative analysis of CD31, CD34, and LYVE-1 in the retina of mice in the DM group and STING1−/−/ApoE−/− group. Scale bar=20 μm. B: correlation analysis of STING1 level, aortic plaque size, and retinal thickness in mice. ***P<0.001.
| 1 |
Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention[J]. Nat Rev Cardiol, 2023, 20 (10): 685- 695.
doi: 10.1038/s41569-023-00877-z |
| 2 |
Ma C, Li Y, Tian M, et al. Gsα regulates macrophage foam cell formation during atherosclerosis[J]. Circ Res, 2024, 134 (7): e34- e51.
doi: 10.1161/circresaha.123.323156 |
| 3 |
Nurmohamed NS, Gaillard EL, Malkasian S, et al. Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation[J]. JAMA Cardiol, 2024, 9 (9): 826- 834.
doi: 10.1001/jamacardio.2024.1874 |
| 4 |
Camaré C, Pucelle M, Nègre-Salvayre A, et al. Angiogenesis in the atherosclerotic plaque[J]. Redox Biol, 2017, 12, 18- 34.
doi: 10.1016/j.redox.2017.01.007 |
| 5 |
Aplin AC, Nicosia RF. Tissue oxygenation stabilizes neovessels and mitigates hemorrhages in human atherosclerosis-induced angiogenesis[J]. Angiogenesis, 2023, 26 (1): 63- 76.
doi: 10.1007/s10456-022-09851-8 |
| 6 | Yu W, Yang B, Xu S, et al. Diabetic retinopathy and cardiovascular disease: a literature review[J]. Diabetes Metab Syndr Obes, 2023, 16, 4247- 4261. |
| 7 |
Simó R, Stitt AW, Gardner TW. Neurodegeneration in diabetic retinopathy: does it really matter?[J]. Diabetologia, 2018, 61 (9): 1902- 1912.
doi: 10.1007/s00125-018-4692-1 |
| 8 |
Zhang R, Kang R, Tang D. STING1 in different organelles: location dictates function[J]. Front Immunol, 2022, 13, 842489.
doi: 10.3389/fimmu.2022.842489 |
| 9 |
Zhang R, Kang R, Tang D. The STING1 network regulates autophagy and cell death[J]. Signal Transduct Target Ther, 2021, 6 (1): 208.
doi: 10.1038/s41392-021-00613-4 |
| 10 |
Barber GN. STING: infection, inflammation and cancer[J]. Nat Rev Immunol, 2015, 15 (12): 760- 770.
doi: 10.1038/nri3921 |
| 11 |
Chen Y, Yue S, Yu L, et al. Regulation and function of the cGAS-STING pathway: mechanisms, post-translational modifications, and therapeutic potential in immunotherapy[J]. Drug Des Devel Ther, 2025, 19, 1721- 1739.
doi: 10.2147/DDDT.S501773 |
| 12 |
简武, 何璐, 屈洪涛, 等. STING通路在心血管疾病中作用的研究进展[J]. 中国心血管杂志, 2025, 30 (1): 106- 111.
doi: 10.3969/j.issn.1007-5410.2026.01.021 |
| 13 |
Pham PT, Fukuda D, Nishimoto S, et al. STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases[J]. Eur Heart J, 2021, 42 (42): 4336- 4348.
doi: 10.1093/eurheartj/ehab249 |
| 14 |
Cai D, Liu H, Wang J, et al. Balasubramide derivative 3C attenuates atherosclerosis in apolipoprotein E-deficient mice: role of AMPK-STAT1-STING signaling pathway[J]. Aging (Albany NY), 2021, 13 (8): 12160- 12178.
doi: 10.18632/aging.202929 |
| 15 | 薛愚愚, 叶璐, 叶河江. cGAS-STING信号通路在眼科疾病中的作用研究进展[J]. 眼科新进展, 2024, 44 (12): 999- 1004. |
| 16 |
Liu H, Ghosh S, Vaidya T, et al. Activated cGAS/STING signaling elicits endothelial cell senescence in early diabetic retinopathy[J]. JCI Insight, 2023, 8 (12): e168945.
doi: 10.1172/jci.insight.168945 |
| 17 |
杨燕, 陈正涛, 肖华胜, 等. 糖尿病大血管病变小鼠模型研究进展[J]. 中国实验动物学报, 2023, 31 (9): 1194- 1205.
doi: 10.3969/j.issn.1005-4847.2023.09.011 |
| 18 |
Furman BL. Streptozotocin-induced diabetic models in mice and rats[J]. Curr Protoc, 2021, 1 (4): e78.
doi: 10.1002/cpz1.78 |
| 19 |
乔羽, 王晓磊, 吴长江, 等. 葛根-丹参对糖尿病相关动脉粥样硬化小鼠脂肪因子稳态的影响[J]. 中国病理生理杂志, 2024, 40 (12): 2238- 2244.
doi: 10.3969/j.issn.1000-4718.2024.12.006 |
| 20 |
Sun Z, Li L, Wu Y, et al. Acetylation-ubiquitination crosstalk of DJ-1 mediates microcalcification formation in diabetic plaques via collagen-matrix vesicles interaction[J]. Cardiovasc Res, 2025, 121 (2): 296- 310.
doi: 10.1093/cvr/cvae263 |
| 21 |
Xie J, Ikram MK, Cotch MF, et al. Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: a systematic review and meta-analysis[J]. JAMA Ophthalmol, 2017, 135 (6): 586- 593.
doi: 10.1001/jamaophthalmol.2017.0988 |
| 22 |
An Y, Xu BT, Wan SR, et al. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction[J]. Cardiovasc Diabetol, 2023, 22 (1): 237.
doi: 10.1186/s12933-023-01965-7 |
| 23 |
Batty M, Bennett MR, Yu E. The role of oxidative stress in atherosclerosis[J]. Cells, 2022, 11 (23): 3843.
doi: 10.3390/cells11233843 |
| 24 |
Seo H, Park SJ, Song M. Diabetic retinopathy (DR): mechanisms, current therapies, and emerging strategies[J]. Cells, 2025, 14 (5): 376.
doi: 10.3390/cells14050376 |
| 25 |
Kinuthia UM, Wolf A, Langmann T. Microglia and inflammatory responses in diabetic retinopathy[J]. Front Immunol, 2020, 11, 564077.
doi: 10.3389/fimmu.2020.564077 |
| 26 |
Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies[J]. Pharmacol Rev, 2021, 73 (3): 924- 967.
doi: 10.1124/pharmrev.120.000096 |
| 27 |
Gui F, You Z, Fu S, et al. Endothelial dysfunction in diabetic retinopathy[J]. Front Endocrinol (Lausanne), 2020, 11, 591.
doi: 10.3389/fendo.2020.00591 |
| 28 |
Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression[J]. Nat Med, 2001, 7 (4): 425- 429.
doi: 10.1038/86490 |
| 29 | Valiatti FB, Crispim D, Benfica C, et al. The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy[J]. Arq Bras Endocrinol Metabol, 2011, 55 (2): 106- 113. |
| 30 |
Chen C, Xu P. Cellular functions of cGAS-STING signaling[J]. Trends Cell Biol, 2023, 33 (8): 630- 648.
doi: 10.1016/j.tcb.2022.11.001 |
| 31 |
Oduro PK, Zheng X, Wei J, et al. The cGAS-STING signaling in cardiovascular and metabolic diseases: future novel target option for pharmacotherapy[J]. Acta Pharm Sin B, 2022, 12 (1): 50- 75.
doi: 10.1016/j.apsb.2021.05.011 |
| 32 |
Ablasser A, Goldeck M, Cavlar T, et al. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING[J]. Nature, 2013, 498 (7454): 380- 384.
doi: 10.1038/nature12306 |
| 33 |
Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway[J]. Science, 2013, 339 (6121): 786- 791.
doi: 10.1126/science.1232458 |
| 34 |
Burdette DL, Monroe KM, Sotelo-Troha K, et al. STING is a direct innate immune sensor of cyclic di-GMP[J]. Nature, 2011, 478 (7370): 515- 518.
doi: 10.1038/nature10429 |
| 35 | Moretti J, Roy S, Bozec D, et al. STING senses microbial viability to orchestrate stress-mediated autophagy of the endoplasmic reticulum [J]. Cell, 2017, 171(4): 809-823. e13. |
| 36 |
Tapia PJ, Martina JA, Contreras PS, et al. TFEB and TFE3 regulate STING1-dependent immune responses by controlling type I interferon signaling[J]. Autophagy, 2025, 21 (9): 2028- 2045.
doi: 10.1080/15548627.2025.2487036 |
| 37 |
Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling[J]. Nat Rev Mol Cell Biol, 2020, 21 (9): 501- 521.
doi: 10.1038/s41580-020-0244-x |
| 38 |
Balka KR, Louis C, Saunders TL, et al. TBK1 and IKKε act redundantly to mediate STING-induced NF-κB responses in myeloid cells[J]. Cell Rep, 2020, 31 (1): 107492.
doi: 10.1016/j.celrep.2020.03.056 |
| 39 |
Liu Y, Carmona-Rivera C, Seto NL, et al. Role of STING deficiency in amelioration of mouse models of lupus and atherosclerosis[J]. Arthritis Rheumatol, 2025, 77 (5): 547- 559.
doi: 10.1002/art.43062 |
| 40 |
Fan X, Han J, Zhong L, et al. Macrophage-derived GSDMD plays an essential role in atherosclerosis and cross talk between macrophages via the mitochondria-STING-IRF3/NF-κB axis[J]. Arterioscler Thromb Vasc Biol, 2024, 44 (6): 1365- 1378.
doi: 10.1161/ATVBAHA.123.320612 |
| 41 | Lin W, Szabo C, Liu T, et al. STING trafficking activates MAPK-CREB signaling to trigger regulatory T cell differentiation [J]. Proc Natl Acad Sci U S A, 2024, 121(29): e2320709121. |
| 42 |
Lee BJ, Byeon HE, Cho CS, et al. Histamine causes an imbalance between pro-angiogenic and anti-angiogenic factors in the retinal pigment epithelium of diabetic retina via H4 receptor/p38 MAPK axis[J]. BMJ Open Diabetes Res Care, 2020, 8 (2): e001710.
doi: 10.1136/bmjdrc-2020-001710 |
| 43 |
Shami A, Gonçalves I, Hultgårdh-Nilsson A. Collagen and related extracellular matrix proteins in atherosclerotic plaque development[J]. Curr Opin Lipidol, 2014, 25 (5): 394- 399.
doi: 10.1097/MOL.0000000000000112 |
| 44 |
Chistiakov DA, Orekhov AN, Bobryshev YV. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability[J]. Acta Physiol (Oxf), 2015, 213 (3): 539- 553.
doi: 10.1111/apha.12438 |
| 45 |
Migdalski A, Jawien A. Neovascularization as a leading mechanism of intraplaque hemorrhage and carotid plaque destabilization: a narrative review[J]. Curr Vasc Pharmacol, 2024, 22 (6): 377- 385.
doi: 10.2174/0115701611304241240523045704 |
| 46 |
Li B, Lu M, Wang H, et al. Macrophage ferroptosis promotes MMP2/9 overexpression induced by hemin in hemorrhagic plaque[J]. Thromb Haemost, 2024, 124 (6): 568- 580.
doi: 10.1055/a-2173-3602 |
| 47 |
王苏涵, 张乐颖, 秦婷婷, 等. VEGF在糖尿病视网膜病变破坏血-视网膜屏障机制中的研究新进展[J]. 国际眼科杂志, 2024, 24 (8): 1260- 1265.
doi: 10.3980/j.issn.1672-5123.2024.8.15 |
| [1] | Yujie YANG, Lili ZHANG, Xinyun PAN, Yingpeng DING, Zhongqun WANG. Advances in the construction and application of animal models for diabetic macrovascular complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(8): 1127-1134. |
| [2] | Yuanjun ZHANG, Jing MA, Juxiang LIU, Jinxin QUAN. Advances in the molecular pharmacological mechanisms of Chinese herbal monomers targeting diabetes-related signal transduction pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(8): 1135-1143. |
| [3] | Ling CHEN, Zhongqun WANG. SGLT2 inhibitor from a clinical research perspective: boundary-breaking pioneer in the treatment of diabetic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 722-728. |
| [4] | Su GUO, Xiaojiang QIN, Xuelu JIANG, Mengwei FANG, Zhi MAN, Xin MENG, Zhifa ZHENG, Liangyuan ZHAO, Yiwei SHI, Xiaomin HOU. Research progress on flavonoids in the prevention and treatment of diabetic microvascular complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 752-763. |
| [5] | Jun WU, Yuwei SONG, Hongbiao LIANG, Juan FENG. Trimethylamine-N-oxide and vascular remodeling in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 774-781. |
| [6] | Yao WU, Xuan ZHOU, Xiaoyan WANG, Daidi WANG, Zhen SUN. Correlation between high density lipoprotein-related ratio index and in-stent restenosis in diabetic patients after percutaneous coronary intervention [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 789-797. |
| [7] | Guangwei QI, Wanyu TONG, Jilu WANG, Jingwen GUO, Ruiqiao LI, Qilong WANG. Protective effects of Xueshuantong on mitochondrial dynamic balance, endothelial dysfunction, and atherosclerosis in diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 798-807. |
| [8] | Yan LIU, Xiaojiang QIN, Chengjie WEI, Xuelu JIANG, Zhifa ZHENG, Xiaoyang PENG, Liangyuan ZHAO, Yiwei SHI, Xiaomin HOU. Research progress on drug molecular targeted delivery systems for cardiovascular complications of diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 808-820. |
| [9] | Xinyun PAN, Yunjian SONG, Zhongqun WANG. Research progress on macrophage membrane nanoparticles in the treatment of diabetic cardiovascular complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 821-826. |
| [10] | Ailin LU, Mengrui YUAN, Yongqing WU, Hongyi LIU. Progress of Chinese medicine intervention in HMGB1 pathway to improve type 2 diabetes mellitus and its complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 827-835. |
| [11] | Mei CHENG, Zhaohui FANG, Jindong ZHAO, Fengxia SHENG, Mengnan MA. Liraglutide combined with metformin on glycolipid metabolism level and intima-media thickness in overweight/obese patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 623-630. |
| [12] | Ying ZHOU, Juntong LIU, Qingfeng WANG, Yufeng YANG, Yan SHI. Research progress on pharmacological mechanism of traditional Chinese medicine targeting type 2 diabetes related pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 500-508. |
| [13] | Fandong MENG, Jingjing FAN, Xin LIU, Lulu KONG. Predicting dual response failure to semaglutide in obese type 2 diabetes: development and validation of a visual scoring system [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1377-1384. |
| [14] | Ziyu WU, Ting YU, Mouwei ZHENG, Tailin GUO. Metformin inhibits diabetes induced ferroptosis in renal proximal tubular epithelial cells by up-regulating Nrf2 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 40-47. |
| [15] | LIU Xing, CHEN Ying. Drug therapy and new technology progress of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1215-1223. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||